Ozempic® (semaglutide), Wegovy® (semaglutide), Mounjaro® (tirzepatide), and Zepbound® (tirzepatide), and Generic Liraglutide are not compounded. Ozempic®, Mounjaro®, and Generic Liraglutide are FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight loss at a healthcare provider’s discretion. Wegovy® and Zepbound® are FDA-approved for weight loss. Ozempic® and Wegovy® are the registered trademarks of Novo Nordisk A/S.  Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Oak Longevity is not affiliated with or endorsed by Novo Nordisk A/S or Eli Lilly and Company. 

Prescription products require an online consultation with a healthcare provider who will determine if a prescription is appropriate for you.